miR-146a mimics attenuate allergic airway inflammation by impacting ILC2 via IRAK1/TRAF6 pathways, while miR-146a inhibitors attenuate asthma via activating TLR2-signaling pathways in inflammatory monocytes. Here, TLR2 is linked to asthma.